The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CHEMBL49289     methyl2-[4-[2-[[2-(3- chlorophenyl)-2...

Synonyms: AGN-PC-002ODD, AG-H-73859, SureCN4611391, Brl-35135, C20H24ClNO4, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Brl35135A

  • 3. Treatment with BRL 35135 reduced weight gain by 19%, increased brown adipose tissue thermogenic activity 45-fold and reduced plasma insulin by 50% [1].
  • No significant changes in body weight occurred during the 10-day treatment with BRL 35135 [2].
  • Effect of the beta-adrenoceptor agonist BRL-35135 on development of obesity in suckling Zucker (fa/fa) rats [3].

High impact information on Brl35135A

  • BRL 35135 produces a dose-related increase in energy expenditure in rodents and, in genetically obese (ob/ob) mice, a dose of 0.5 has significant antiobesity activity [4].
  • After s.c. administration of 3 mg/kg of the selective, rodent specific beta3-AR agonists BRL 35135, CL 316, 243 or ICI 198,157, WT mice exhibited a significant decrease in the extent of movement of radiotracer through the stomach and intestines, indicative of decreased GI motility [5].
  • Acute effects of the beta 3-adrenoceptor agonist, BRL 35135, on tissue glucose utilisation [6].
  • Higher doses of ZD 7114 and BRL 35135 produced no further increase in HSL activity and, in the case of BRL 35135, provoked symptoms of non-selective beta-adrenoceptor activation [7].
  • Food intake was significantly reduced in the BRL 35135-treated-exercise-trained animals, although neither beta 3-agonist nor exercise alone affected it.(ABSTRACT TRUNCATED AT 250 WORDS)[1]

Chemical compound and disease context of Brl35135A


Biological context of Brl35135A


Anatomical context of Brl35135A


Associations of Brl35135A with other chemical compounds


Gene context of Brl35135A


Analytical, diagnostic and therapeutic context of Brl35135A


  1. Potentiation of the anti-obesity effect of the selective beta 3-adrenoceptor agonist BRL 35135 in obese Zucker rats by exercise. Santti, E., Huupponen, R., Rouru, J., Hänninen, V., Pesonen, U., Jhanwar-Uniyal, M., Koulu, M. Br. J. Pharmacol. (1994) [Pubmed]
  2. Effects of BRL 35135, a beta-adrenoceptor agonist with novel selectivity, on glucose tolerance and insulin sensitivity in obese subjects. Mitchell, T.H., Ellis, R.D., Smith, S.A., Robb, G., Cawthorne, M.A. International journal of obesity. (1989) [Pubmed]
  3. Effect of the beta-adrenoceptor agonist BRL-35135 on development of obesity in suckling Zucker (fa/fa) rats. Charon, C., Dupuy, F., Marie, V., Bazin, R. Am. J. Physiol. (1995) [Pubmed]
  4. BRL 35135, a potent and selective atypical beta-adrenoceptor agonist. Cawthorne, M.A., Sennitt, M.V., Arch, J.R., Smith, S.A. Am. J. Clin. Nutr. (1992) [Pubmed]
  5. Beta-3 adrenergic receptor agonists cause an increase in gastrointestinal transit time in wild-type mice, but not in mice lacking the beta-3 adrenergic receptor. Fletcher, D.S., Candelore, M.R., Grujic, D., Lowell, B.B., Luell, S., Susulic, V.S., Macintyre, D.E. J. Pharmacol. Exp. Ther. (1998) [Pubmed]
  6. Acute effects of the beta 3-adrenoceptor agonist, BRL 35135, on tissue glucose utilisation. Liu, Y.L., Stock, M.J. Br. J. Pharmacol. (1995) [Pubmed]
  7. Selective activation of brown adipocyte hormone-sensitive lipase and cAMP production in the mouse by beta 3-adrenoceptor agonists. Shih, M.F., Taberner, P.V. Biochem. Pharmacol. (1995) [Pubmed]
  8. Acute injection of beta-adrenoceptor agonist BRL 35135 corrects both impaired uncoupling protein and lipoprotein lipase gene expression but not hypercapacity of lipogenesis in brown adipose tissue of suckling fa/fa rats. Marie, V., Dupuy, F., Bazin, R. Int. J. Obes. Relat. Metab. Disord. (1994) [Pubmed]
  9. Beta-adrenoceptor subtypes mediating the airways response to BRL 35135 in man. Newnham, D.M., Ingram, C.G., Mackie, A., Lipworth, B.J. British journal of clinical pharmacology. (1993) [Pubmed]
  10. Chronic treatment with BRL 35135 potentiates the action of insulin on lipid metabolism. Virtanen, K.A., Rouru, J., Hänninen, V., Savontaus, E., Rouvari, T., Teirmaa, T., Koulu, M., Huupponen, R. Eur. J. Pharmacol. (1997) [Pubmed]
  11. Beta-adrenoceptor subtypes mediating the metabolic effects of BRL 35135 in man. Wheeldon, N.M., McDevitt, D.G., McFarlane, L.C., Lipworth, B.J. Clin. Sci. (1994) [Pubmed]
  12. The effects of the beta3-adrenoceptor agonist BRL 35135 on UCP isoform mRNA expression. Emilsson, V., Summers, R.J., Hamilton, S., Liu, Y.L., Cawthorne, M.A. Biochem. Biophys. Res. Commun. (1998) [Pubmed]
  13. The rat lipolytic beta-adrenoceptor: studies using novel beta-adrenoceptor agonists. Wilson, C., Wilson, S., Piercy, V., Sennitt, M.V., Arch, J.R. Eur. J. Pharmacol. (1984) [Pubmed]
  14. Effect of BRL-35135 on LTB4-induced guinea pig eosinophil chemotaxis. Sugasawa, T., Morooka, S. Agents Actions (1992) [Pubmed]
  15. Differential regulation of uncoupling proteins by chronic treatments with beta 3-adrenergic agonist BRL 35135 and metformin in obese fa/fa Zucker rats. Savontaus, E., Rouru, J., Boss, O., Huupponen, R., Koulu, M. Biochem. Biophys. Res. Commun. (1998) [Pubmed]
  16. Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice. Moore, G.B., Chapman, H., Holder, J.C., Lister, C.A., Piercy, V., Smith, S.A., Clapham, J.C. Biochem. Biophys. Res. Commun. (2001) [Pubmed]
WikiGenes - Universities